Name: Anti-FGF23 Antibody, Non-Fucosylated
SKU: BioBet-013ZP
Rating: 5 (1 reviews)

Target

FGF23

Isotype

IgG1

Description

Anti-FGF23 Antibody, Non-Fucosylated (BioBet-013ZP) is a human monoclonal IgG1 antibody against FGF23. This product is an ADCC enhanced antibody produced by our Afuco™ platform.

Antibody Indication

X-linked hypophosphataemia

Classification

Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced FGF23 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.

Official Name

FGF23

Full Name

Fibroblast growth factor 23

Background

This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC).

Alternative Names

ADHR; FGFN; HYPF; HFTC2; HPDR2; PHPTC

Gene ID

8074

UniProt ID

Q9GZV9

Cellular Localization

Extracellular region or secreted

Involvement in Disease

Diseases associated with FGF23 include Hypophosphatemic Rickets, Autosomal Dominant and Tumoral Calcinosis, Hyperphosphatemic, Familial, 2.

Related Pathways

Its related pathways are RET signaling and Signaling by FGFR2 in disease.

Function

Regulator of phosphate homeostasis. Inhibit renal tubular phosphate transport by reducing the level of SLC34A1. Up-regulate the expression of EGR1 in the presence of KL (via similarity). Acts directly on the parathyroid glands, reducing parathyroid secretion (similar). Vitamin d metabolism regulator. Negatively regulate osteoblast differentiation and matrix mineralization.

Field of research

Cancer antibody; Controls and Markers antibody; Developmental Biology antibody; Signaling Transduction antibody

Post-translational modifications

1.Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases. 2.O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23.

Biologic Classification

Protein Based Therapies
Monoclonal antibody (mAb)

Antibody Isotype

IgG1

Antibody Clone

BioBet-013ZP

Host

Human

Species Reactivity

Human

Description

Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that specifically binds fibroblast growth factor 23 (FGF23). The U.S. Food and Drug Administration approved Burosumab for the treatment of X-linked hypophosphatemia (XLH) in 2018. It is a rare inherited disease that affects approximately 3,000 children and 12,000 adults in the United States. Burosumab is a breakthrough therapy classified as an orphan drug.

Antibody Indication

X-linked hypophosphataemia

Anti-FGF23 Antibody, Non-Fucosylated (CAT#: BioBet-013ZP) Datasheet

ADCC-Enhanced Antibody

Target

Antibody Specifications

Indication

ONLINE INQUIRY